investment risk

Cannabis rescheduling offers hope but legalization remains years away. Tilray investors shouldn't bet on near-term U.S. market entry.

SpaceX and OpenAI IPOs loom in 2026 with record valuations. Historical data shows the 10 largest U.S. IPOs declined 26% median in year one.

Small-cap biotech like CTMX offers explosive growth potential but carries significant risk; megacap pharma like JNJ provides stability and dividends with moderate returns.

S&P 500 and Nasdaq hit all-time highs amid 13-day Nasdaq winning streak, but Shiller P/E Ratio at 155-year extremes signals caution as historically-equivalent valuations preceded 20%+ declines.

ProShares Ultra S&P 500 ($SSO) offers 14.5% average annual returns but amplifies losses. Year-to-date decline of 9% versus 3.8% for standard S&P 500 raises questions about long-term viability.

FuboTV stock plunges as sports-focused streamer battles profitability pressures amid competition from Netflix, Disney, and Amazon.

SpaceX prepares for record IPO at $2 trillion valuation, but analysts cite extreme 130x price-to-sales ratio and Musk's execution concerns as major headwinds.

SpaceX confidentially files for IPO with $1.75 trillion valuation, seeking $50-75B. Analyst raises concerns over valuation metrics and leadership execution track record.

TQQQ's 41% average annual returns could theoretically turn $10K into $1M in 14 years, but leveraged ETFs carry amplified volatility and decay risks unsuitable for most investors.

SpaceX's reported $1.75 trillion IPO valuation raises concerns about overpriced future promises, Elon Musk's divided focus, and regulatory uncertainties in space exploration.

Tech stocks retreated from peaks but remain priced for significant 2026 AI earnings growth. Forward P/E of ~24x looks reasonable, yet popular AI stocks offer no margin for error.

XRP offers stronger fundamentals with institutional adoption for payments, while Shiba Inu remains a speculative meme coin with no real utility, making XRP the better crypto downside play.

Amazon plans $200B AI infrastructure spending in 2026—53% above analyst estimates—risking shareholder returns if deployment disappoints.

IonQ posts 429% YoY revenue growth to $62M, projects $235M next year. Quantum leader faces commercialization uncertainty; experts suggest cautious 1% position sizing.

VWOB's 11.6% return outpaces BND's 6.1%, but 41% junk-rated holdings create higher risk. BND offers safer diversification for conservative investors.

Tesla's 2,760% decade run faces headwinds as 367 P/E ratio requires 31% annual growth through 2035, dependent on uncertain autonomous driving and robotics ventures.

Nvidia's $62.3B data center revenue represents 91% of total sales, creating extreme dependence on AI infrastructure spending and significant valuation risk if growth disappoints.

Regencell Bioscience surged 21,000% despite zero revenue and no approved products, exemplifying speculative excess that investors should avoid.

Invesco QQQ Trust has delivered 18% annual returns since 2011, far outpacing the S&P 500's 13.6%, but analysts caution exceptional gains may not persist.

Analysis flags Rivian, Snowflake, Lucid, Palantir, DoorDash, Upstart, and Carvana as overvalued despite weak free cash flow generation, signaling potential volatility ahead.